Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Humacyte, Inc. (NASDAQ: HUMA) securities.
If you suffered a loss on your Humacyte, Inc. investment and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
THE LAWSUIT: May 10 2024 - Oct 17 2024
CASE DETAILS: The filed complaint alleges that Humacyte, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company’s Durham, North Carolina facility failed to comply with good manufacturing practices, including quality assurance and microbial testing; (2) the FDA’s review of the biologics license application would be delayed while Humacyte remediated these deficiencies; and (3) as a result, there was a substantial risk to FDA approval of acellular tissue engineered vessel for vascular trauma; and (4) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





